Follow us on Twitter
This page is updated frequently with new Cirrhosis-related patent applications. Subscribe to the Cirrhosis RSS feed to automatically get the update: related Cirrhosis RSS feeds. RSS updates for this page: Cirrhosis RSS
|| List of recent Cirrhosis-related patents
|Methods for the treatment and prevention of liver disease|
The presently disclosed invention is directed to the discovery that hepatocyte nuclear factor 4 alpha (hnf4α; also known as nr2a1), a transcription factor, reverses hepatocyte dysfunction in an animal model of cirrhosis, resulting in improvement in hepatic function, treatment of cirrhosis, and prolonged survival.. .
|Lysosomal acid lipase therapy for nafld and related diseases|
The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating the metabolic syndrome.
|Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists|
The present invention provides 4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as v1a receptor modulators, and in particular as v1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior..
|Anti-c-met antibody having hgf activity and use thereof|
Disclosed are a human antibody comprising a human complementarity-determining region (cdr), which binds specifically to c-met, and a framework region (fr), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody b7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-met-specific human antibody can function as an hgf mimic that can be used as a wound healing composition.
|Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis|
In various embodiments, the present invention provides methods of treating and/or preventing nash and/or pbc comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.. .
|Prevention and treatment of inflammatory conditions|
The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ald). More specifically the present embodiments relate to the prevention and treatment of ald through the administration of an retinoic acid receptor (rar) agonist.
|Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction|
A systems biology approach is used to characterize and relate the intestinal (gut) microbiome of a host organism (e.g. A human) to physiological processes within the host.
|Method for the detection of enzymatic activity with magnetically functionalized substrates|
The present invention provides methods for detecting an enzymatic activity, the method including combining at least one magnetic particle to an enzyme substrate to form a magnetically modified substrate, reacting the magnetically modified substrate with at least one enzyme; and detecting a change in a magnetic property of the magnetically modified substrate or its cleavage products, thereby detecting an activity of said at least one enzyme, wherein the method may be applied to a human subject to detect a disease selected from the group consisting of rheumatitis, arthritis, an injury, dupuytren's disease, peyronie's disease, a collagen related disease, steatosis, fibrosis, cirrhosis, metastasis, tissue regeneration, cancer, coronary disease, a liver disease, a metabolic condition, an infection and an inflammatory disease.. .
Disclosed herein is a method for diagnosing hepatic cancer by analysing a sample and determining the level of at least one compound selected from the group consisting of glycine, trimethylamine-n-oxide, hippurate and citrate and comparing the levels in the sample with control levels. The analysis of the sample can involve the determination of a profile for the sample.
|Pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative thereof|
The present invention provides a new use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative thereof. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including mmps and timps, and so it can inhibit liver fibrosis.
|2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections|
The present invention relates to 2′-fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including hepatitis b virus (hbv) and secondary disease states and conditions thereof (cirrhosis and liver cancer), heptatitis c virus (hcv), herpes simplex virus i and ii (hsv-1 and hsv-2), cytomegalovirus (cmv), varicella-zoster virus (vzv) and epstein barr virus (ebv) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially hbv.. .
|Biomarkers for inflammation of the liver|
The invention relates to a method for the diagnostic investigation of biological samples from a person for inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where the sample is investigated for one or more proteins as markers of inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where a concentration of the proteins which is elevated or decreased by comparison with the healthy state indicates the presence of an inflammation of the liver, in particular a hepatic fibrosis and/or cirrhosis of the liver.; the proteins are selected from the group of er6q, vimentin, actin alpha 1 skeletal muscle protein, hmfap 4, tropomyosin, ptges 2, amyloid p component, transgelin, calponin 1, homo sapiens p20 protein, 17 kda myosin light chain, h chain h igg b12, prolyl 4-hydroxylase, beta subunit methylenetetrahydrofolate dehydrogenase 1, pro2619, aldehyde dehydrogenase 1, fibrinogen alpha chain preproprotein, fructose-bisphosphate aldolase b, argininosuccinate synthetase, eefla2, at p 5 al, alpha-2 actin, regucalcin, serum albumin, mitochondrial malate dehydrogenase, mitochondrial acetoacetyl-coa thiolase or in each case a partial sequence thereof.. .
|Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection|
The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including hepatitis b and hepatitis c viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions..
|Methods for improving liver function|
The present invention provides methods to improve liver function utilizing tocotrienols. In particular, various liver pathologies may be treated using the present methods, including cirrhosis, hepatitis, and sclerosing cholangtitis.
|Ligands that bind tgf-beta receptor ii|
The disclosure provides an anti-tgfbetarii immunoglobulin single variable domain. Suitably, an anti-tgfbetarii immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of seq id no:1-28 having up to 5 amino acid substitutions, deletions or additions.
A compound having the structure (i) useful for treating hypertension, pulmonary arterial hypertension, congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.. .
|Diazeniumdiolate heterocyclic derivatives|
A compound having the structure: useful for treating hypertension, pulmonary arterial hypertension (pah), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.. .
|Methods and compositions for the treatment of cirrhosis and liver fibrosis|
The invention provides a method for the treatment of cirrhosis and liver fibrosis by the use or viral vectors containing the gene encoding igf-i. The invention discloses both parvoviral vectors and sv40-based vectors as well uses thereof for the treatment of cirrhosis and gene therapy and methods for the preparation of said viral vectors..
|Method for enhancing the performance and general condition of a subject|
The invention concerns the therapy with a cardiac resynchronization device (crt) and/or therapy with an automated internal cardiac defibrillator (icd) for treating patients with any cancer or patients with cachexia due to acute or chronic illness other than cardiac illness, including malignant tumor disease, copd, chronic renal failure, liver cirrhosis, chronic infections, and/or aids. Areas of application are the life sciences, in particular medicine and medical technology..
|Fused tricyclic compounds as adenosine receptor antagonist|
The present disclosure relates to fused tricyclic compounds of formula (i) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as a2a adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine a2a receptor.
|Marker consisting of plasma microrna and a new method for diagnosis of hepatocellular carcinoma|
The present invention relates to a kit for diagnosing hepatocellular carcinoma consisting of plasma microrna, a kit containing the same, and a new method therefor. The marker for diagnosing hepatocellular carcinoma consists of a plurality of nucleic acid molecules, each nucleic acid molecule encoding at least one microrna sequence, preferably consists of nucleic acid molecules encoding hsa-mir-122, hsa-mir-192, hsa-mir-21, hsa-mir-223, hsa-mir-26a, hsa-mir-27a, hsa-mir-801 and hsa-mir-1228.
|Soluble guanylate cyclase activators|
This inventions relates to compounds having the structure formula i and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver..
|Compositions and methods for modulating autophagy|
In alternative embodiments, the invention provides cell-permeable recombinant or synthetic proteins to modulate autophagy, including a tat-atg5k130r (inhibitor of autophagy) and a tat-beclin 1 (stimulant or activator of autophagy), and nucleic acids expressing them and methods for making and using them, e.g., to treat conditions and disorders responsive to autophagy modulation (e.g., where autophagy is dysregulated), including neurodegeneration, cystic fibrosis, cancer, heart failure, diabetes, obesity, sarcopenia, aging, ischemia/reperfusion, inflammatory disorders including crohns, ulcerative colitis, biliary cirrhosis, lysosomal storage diseases, infectious diseases associated with intracellular pathogens including viruses, bacteria, and parasites such as trypanosomes and malaria.. .
|Methods for modeling hepatic inflammation|
Provided herein are in silico methods of modeling hepatic inflammation, fibrosis/cirrhosis, and cancer. The models are computer-implemented agent-based models and are useful in determining patient prognoses in hepatic conditions, including viral infections, damage, inflammation, and cancer.
|Fumarylacetoacetate hydrolase (fah)-deficient pigs and uses thereof|
Described herein is the generation of fah+/− heterozygote pigs by homologous recombination and somatic cell nuclear transfer, and a method for producing fah−/− homozygote pigs. The fah-deficient pigs of the disclosure can be used for a variety of research and therapeutic purposes, such as for the expansion of human hepatocytes, and as large animal models of hereditary tyrosinemia type 1, cirrhosis and hepatocellular carcinoma..
|Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders|
Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of s1p1-associated disorders, for example, psoriasis, rheumatoid arthritis, crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type i diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer.. .
|Methods relating to identification of susceptibility to liver injury|
The present invention relates to methods for identifying susceptibility of impaired hepatic wound healing in a patient, most particularly by identifying modifications of the of ppar-γ and tgfβ1 genes. It further relates to stratifying populations of patients to determine susceptibility to impaired hepatic wound healing and direct appropriate healthcare resources.
|Ex-vivo method for the early diagnosis of minimal hepatic encephalopathy by means of the determination of the 3-nitrotyrosine in serum|
An ex-vivo method for the early diagnosis of minimal hepatic encephalopathy by means of determining serum 3-nitrotyrosine relates to an ex-vivo method for the detection and early diagnosis of minimal hepatic encephalopathy (mhe) in patients with liver diseases, including cirrhosis, based on the presence of specific serum biomarkers, specifically by means of determining 3-nitrotyrosine (3-nt), which comprises obtaining serum or plasma obtained from the blood of patients and controls, and determining whether or not the measurement of the concentration of 3-nitrotyrosine obtained is greater than a specific level.. .
|Epigenetic mechanisms of anti-fibrotic action for the liver|
This invention demonstrates the therapeutic efficacy of yang-gan-wan (ygw) and its active components, especially in the formulation provided by sheng-pu pharmaceutials, inc., for treating and preventing liver fibrosis. This invention further demonstrates mecp2 is an important therapeutic target for ygw and its active ingredients' action against liver fibrosis and cirrhosis..
|Galactose-pronged polysaccharides in a formulation for antifibrotic therapies|
Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-pdgf receptors; (ii) synaptophysin; (iii) zvegf3; (iv) ccr1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases mmp 2 and mmp9; (viii) matrix metalloproteinase inhibitors timp1 and tmp2; (ix) integrins; (x) tfg-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.. .
|Liver disease marker, method and apparatus for measuring the same, and method for assaying pharmaceutical preparation|
Disclosed is a method for promptly identifying a liver disease. A normal person or a liver disease such as drug-induced liver injury, asymptomatic hepatitis b carrier, chronic hepatitis b, hepatitis c with persistently normal alt, chronic hepatitis c, cirrhosis type c, hepatocellular carcinoma, simple steatosis, or non-alcoholic steatohepatitis is identified by measuring the concentration of a γ-glu-x (wherein x represents an amino acid or an amine) peptide or the level of ast or alt in blood and carrying out, for example, a multiple logistic regression based on the measured value..
|Compositions and methods for reduced scarring and for treatment of fibrosis|
Methods of treating, reducing or preventing fibrosis or scarring including administering a therapeutic molecular agent selected from the group consisting of an agent that inhibits chaperonin containing tcomplex polypeptide subunit eta polypeptide (“cct-eta”), an agent that inhibits a-smooth muscle actin (“a-sma”), or a combination thereof, are presented. The fibrosis may include dupuytren's contracture, peyronie's disease, pulmonary fibrosis, cirrhosis, interstitial lung disease or scarring alopecia..
|Combination therapy and methods for treatment and prevention of hyperproliferative diseases|
The present invention provides therapy and methods for the treatment and prevention of diseases of cell proliferation such as cancer, benign tumors, and viral diseases such as hiv-aids, hepatitis b, hepatitis c and cirrhosis. The methods of this invention consist of the administration to a patient of a combination of effective amounts of agents capable of eradicating the neoplastic cells, while sparing the non-neoplastic cells from cytotoxic side-effects.
|Deuterium-enriched pyrimidine compounds and derivatives|
And their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer, carcinoid tumors, teratocarcinoma, tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia, fibrotic processes as well as a disease state modulated directly or indirectly with 5-ht receptors, 5-ht1, 5-ht1a, 5-ht2 receptors, 5-ht2a and 5-ht2b receptors, dopamine receptors and multiple kinase pathways.. .
|Use of pedf-derived polypeptides for treating liver cirrhosis|
The present disclosure elucidates that 34-mer pedf suppresses hepatic stellate cells (hscs) from activation by diminishing the levels of alpha-smooth muscle actin (α-smc), collagen type 1, and monocyte chemoattractant protein-1 (mcp-1); and 44-mer pedf promotes liver regeneration process by enhancing the replication of liver-derived progenitor cells (ldpcs). Accordingly, methods and compositions directing to the new use of the 34-mer pedf or 44-mer pedf in patients suffering from liver cirrhosis are provided herein..
|Soluble guanylate cyclase activators|
The invention relates to compounds having the structure of formula (i) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cgmp”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cgmp balance.
|2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections|
The present invention relates to 2′-fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including hepatitis b virus (hbv) and secondary disease states and conditions thereof (cirrhosis and liver cancer), heptatitis c virus (hcv), herpes simplex virus i and ii (hsv-1 and hsv-2), cytomegalovirus (cmv), varicella-zoster virus (vzv) and epstein barr virus (ebv) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.. .
Popular terms: [SEARCH]
Cirrhosis topics: Hypertension, Vascular Disease, Endothelial Dysfunction, Endothelial, Dysfunction, Cardiovascular Disease, Cardiovascular, Hepatocellular Carcinoma, Pharmaceutically Acceptable Salt, Pharmaceutically Acceptable Salts, Nephropathy, Nucleic Acid, Inflammation, Recombinant, Wound Healing
Follow us on Twitter
This listing is a sample listing of patent applications related to Cirrhosis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cirrhosis with additional patents listed. Browse our RSS directory or Search for other possible listings.